Arcellx (ACLX) said Wednesday that a phase 2 study of anitocabtagene autoleucel showed that patients with relapsed or refractory multiple myeloma demonstrated an overall response rate of 97%.
The results also showed a complete response/stringent complete response rate of 68% and a very good partial response or higher rate of 85%, based on International Myeloma Working Group criteria as investigator-assessed, the company said.
Arcellx said no delayed or non-immune effector cell-associated neurotoxicity syndrome neurotoxicities have been observed to date with the therapy.
The company said it plans a commercial launch for the therapy in 2026.
Shares were up 6.2% in recent trading.
Price: 61.86, Change: +3.61, Percent Change: +6.20
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。